Company

Intrinsic LifeSciences is a pioneer in the discovery, development, implementation and commercialization of the first biomarker assay for iron metabolism. Research teams lead by Company founders independently discovered hepcidins in human urine and fish gill tissue over seven years ago, and went on to perform pioneering studies that defined the molecular structure of hepcidin, regulation of hepcidin production, its mechanism of action in iron regulation, and hepcidin's role in disease and infections. The human and bass hepcidin molecules are the only two hepcidins that have been purified, chemically synthesized and refolded into their native bioactive form, and had their 3-D solution structures determined. The founders are the only ones worldwide to have successfully developed polyclonal antibodies to hepcidin in rabbits and monoclonal antibodies in mice. These antibodies bind specifically to hepcidin from human blood and urine enabling a simple and widely practicable immunoassay (ELISA) to be used for direct measurement of hepcidin concentration in human fluids. The company continues to expand their portfolio of related next-gen diagnostic products to further facilitate the research, diagnosis, treatment and monitoring of iron disorders.

Our vision is to be the world's leading provider of innovative in vitro diagnostics and targeted therapeutics for iron overload diseases, anemia, and iron-related inflammatory diseases.

in·trin·sic (n-trnzk, -sk) adj.

Of or relating to the essential nature of a thing.